Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tempol

Phase 2Small molecule

AAdamis Pharmaceuticals Corporation

Tempol is one of 45 small molecule programs targeting ESS. It is currently in Phase 2.

1

Indications

6

Total Trials

2

Active Trials

44

Competitors

Pipeline

Status by Indication[3][1]

Indication

ESSRecruiting

ESSPhase 2

Recruiting

Competition

Competitive Landscape

56 competitors in ESS

#DrugCompanyPhaseTrials

Lexapro

Proamatine

Quviviq

Idorsia Pharmaceuticals Ltd.

Opdualag

Bristol-Myers Squibb

Opdivo

Bristol-Myers Squibb

Darzalex

Johnson & Johnson

Decadron

AAspen Global Incorporated

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Kyprolis

VVirionyx Corporation Limited

Mineral Trioxide Aggregate

JJordan University of Science and Technology

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

ESS

NCT06424756

Clinical

Trials by Indication[1]

Local1 trial

The Effect of Antioxidants on Skin Blood Flow During Local Heating

Completed·TThe University of Texas at Arlington·Phase 1·NCT03680638·44 enrolled

COVID-191 trial

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Terminated·AAdamis Pharmaceuticals Corporation·Phase 2/3·NCT04729595·248 enrolled

ESS1 trial

Effects of an Antioxidant Supplement on Blood Vessel Health

Recruiting·UUniversity of Georgia·Phase 2·NCT06424756·60 enrolled

Toxicities1 trial

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Recruiting·MMatrix Biomed, Inc.·Phase 2·NCT03480971·120 enrolled

Dermatitis1 trial

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01324141·6 enrolled

1 more indication

Metastatic Cancer1 trial

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Available·MMatrix Biomed, Inc.··NCT05491928

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tempol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tempol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tempol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Adamis Pharmaceuticals Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAdamis Pharmaceuticals Corporation

Related News